Milk Thistle vs TUDCA — two very different liver supplements
Milk thistle (silymarin) and TUDCA (tauroursodeoxycholic acid) are routinely lumped under "liver support" but they target different problems by different mechanisms. Silymarin is a flavonolignan antioxidant whose best evidence is in alcohol-related liver disease and supportive care for chronic hepatitis. TUDCA is a synthesized bile-acid derivative — the same chemical class as ursodiol (UDCA), a prescription drug — whose best evidence is in cholestatic disorders, primary biliary cholangitis, and bile-acid-driven hepatocyte injury. They are not interchangeable.
Quick verdict
| Scenario | Better choice | Why |
|---|---|---|
| Cholestatic liver disease / primary biliary cholangitis (adjunct) | TUDCA (under hepatology care) | Bile-acid chemistry; UDCA is the standard of care, TUDCA is the same class with thinner trial data. |
| Alcohol-related liver injury (adjunct to cessation) | Milk thistle (silymarin) | Modest trial-level signal on liver enzymes; cessation is the main intervention. |
| NAFLD / metabolic-associated steatosis | Neither is first-line | Weight loss and metabolic control dominate; silymarin has small-trial signal on ALT. |
| Drug-induced hepatotoxicity (acute) | Neither replaces NAC / standard care | Acute drug-induced liver injury is a hospital problem, not a supplement problem. |
| Gallstone-related cholestasis | TUDCA / UDCA | Bile-acid chemistry directly relevant. |
| General "liver detox" with no diagnosis | Neither | The liver doesn't need "detoxing" in healthy adults; lifestyle and abstinence from hepatotoxins is the work. |
How they actually differ
Mechanism — antioxidant flavonolignan vs bile-acid chaperone
Silymarin is the flavonolignan complex from Silybum marianum. Its proposed mechanisms include free-radical scavenging, membrane stabilisation of hepatocytes, anti-fibrotic activity in stellate cells, and modest anti-inflammatory effects. Silybin (the most-studied silymarin component) has been used intravenously in Amanita phalloides mushroom poisoning under hospital supervision as an antidote — its non-mushroom-poisoning evidence is much weaker.
TUDCA is a taurine-conjugated bile acid synthetically produced or extracted historically from bear bile. It functions as a chemical chaperone reducing endoplasmic-reticulum stress, replaces more cytotoxic hydrophobic bile acids in the bile pool, and improves bile flow in cholestasis. Its prescription cousin UDCA is FDA-approved for primary biliary cholangitis with mortality and transplant-free-survival evidence; TUDCA is sold as a supplement in the US and is licensed as a pharmaceutical in some other jurisdictions.
Evidence base by liver condition
- Alcohol-related liver disease: The 2017 Cochrane review (Rambaldi) of 18 silymarin RCTs in liver disease (mostly alcohol-related and viral) found no significant effect on mortality and inconsistent effects on liver biochemistry. Trial weight is modest.
- NAFLD / NASH: Small RCTs of silymarin at 140–700 mg/day have shown ALT reductions but no consistent histological improvement; weight loss and metabolic control remain first-line.
- Hepatitis C (pre-DAA era): A 2012 Fried JAMA trial found high-dose silymarin no better than placebo for ALT reduction in HCV non-responders.
- Primary biliary cholangitis: UDCA (the prescription bile acid) has robust mortality and transplant-free-survival evidence at 13–15 mg/kg/day. TUDCA has smaller trials suggesting biochemical-marker improvement; it is not a substitute for UDCA in confirmed PBC.
- Cholestasis of pregnancy: UDCA is standard; TUDCA is sometimes used in pregnancy in some jurisdictions but pregnancy-specific safety data are limited. Coordinate with obstetrics/hepatology.
- Amanita mushroom poisoning: IV silibinin (the European hospital product) is used as an antidote. Oral milk thistle supplements are not the same product — this is a hospital intervention.
Dose and form
Silymarin: standardised to 70–80% silymarin content, 140–420 mg/day in divided doses. The "silymarin phytosome" (silybin bound to phosphatidylcholine; Siliphos) provides better absorption at lower doses (240 mg/day equivalent).
TUDCA: 250–1750 mg/day in divided doses; PBC trials of the prescription form used 1500 mg/day. Supplement-grade purity varies widely; choose third-party-tested products if you proceed.
Safety
Silymarin is well-tolerated; the main practical caution is CYP-pathway interaction at higher doses (it can affect drug levels of CYP3A4 substrates and P-glycoprotein substrates) and an additive hypoglycaemic effect with diabetes medications. Allergic reactions in users allergic to the daisy family (ragweed, chrysanthemum) occur.
TUDCA is generally well-tolerated; diarrhoea is the most common adverse effect at higher doses. The bile-acid pharmacology means caution in complete biliary obstruction, severe acute cholecystitis, and active pancreatitis. UDCA/TUDCA can affect absorption of fat-soluble vitamins over time.
Cost
Silymarin runs $0.10–0.40/day. Silymarin phytosome (Siliphos) runs $0.50–1.00/day. TUDCA runs $0.50–2.00/day depending on dose and brand. Prescription UDCA is typically covered by insurance for cholestatic disease and is the cost-effective option when indicated.
What we'd actually do
For any suspected chronic liver disease: get the diagnosis first. Liver enzymes, hepatitis serologies, autoimmune workup, and abdominal imaging are the standard workup. Empirical supplement use without diagnosis routinely misses treatable causes.
For alcohol-related liver disease with cessation in place: silymarin 200 mg twice daily as an adjunct; recheck LFTs at 3–6 months. Stop if no biochemical signal at 6 months.
For cholestatic disease: see a hepatologist. UDCA at evidence-based doses is the standard; TUDCA supplementation is an option to discuss with the prescriber, not a substitute.
For "general liver support" without a diagnosis: neither. Weight management, alcohol minimisation, screening for hepatitis, and review of hepatotoxic medications are the high-value moves.
Sources
- Rambaldi A, et al. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2007;(4):CD003620. PMID: 17943794
- Fried MW, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy. JAMA. 2012;308(3):274–282. PMID: 22797644
- Pares A, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol. 1998;28(4):615–621. PMID: 9566830
- Crosignani A, et al. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis: a dose-response study. Dig Dis Sci. 1996;41(4):809–815. PMID: 8674406
- Larghi A, et al. Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Aliment Pharmacol Ther. 1997;11(2):409–414. PMID: 9146781
- Mato JM, et al. Therapy of liver diseases with S-adenosyl-L-methionine and antioxidants — comparative review. Drug Metab Drug Interact. 2000;17(1-4):29–43. PMID: 11201307